Corona Remedies IPO Closes 137x Subscribed on Day 3

• Corona Remedies IPO closed with a 137x subscription on its final day (Day 3).
• The Rs 655-crore IPO saw strong interest from QIBs (278x), NIIs (209x), and retail investors (29x).
• Grey Market Premium (GMP) for Corona Remedies IPO was reported around 25-30% over the issue price.
• The IPO was an Offer for Sale (OFS) with a price band of Rs 1,008-1,062 per share.
• Analysts recommend the IPO as a long-term investment due to the company's strong presence in chronic therapies and the pharma sector's growth.

Why It Matters: High IPO subscription shows strong investor confidence and potential market gains.